VolitionRx Limited said first-half 2026 revenue rose 112% year over year to $1.4 million, while second-quarter revenue was about $0.4 million, unchanged from a year earlier. Second-quarter operating expenses fell 32%, operating loss narrowed 34% to $4.2 million, and net cash used in operating activities declined 18% to $5.2 million. The company said it is in discussions and technology evaluations with more than a dozen leading diagnostic and liquid biopsy companies as it seeks licensing agreements that could provide upfront milestone payments, royalties and other recurring revenue. Volition also cited a new collaboration with Sysmex Corporation, submission for peer review of a feline lymphoma manuscript tied to a potential $5 million contractual milestone payment, reimbursement work on Nu.Q® Lung Cancer with Hospices Civils de Lyon, and publication of its first peer-reviewed paper on Capture-Seq™.